MDxHealth Reports Q2 2026 Earnings with Revenue Growth but Continued Losses
MDxHealth (NASDAQ: MDXH) reported second-quarter revenue of $27.2 million, a year-over-year increase of 16%, driven by growth in its prostate cancer diagnostics business. Sequentially, the company saw a 14% rise from Q1 2026 to Q2 2026. Despite this progress, MDxHealth posted an operating loss of $5.1 million and a net loss of $9.5 million for the quarter. The decline in gross margin year-over-year was attributed to a shift toward liquid-based tests from tissue-based ones following its acquisition of ExoDx. The company also announced it had eliminated a contingent liability of $10.4 million after closing Delta Laboratories by June 30, 2026. MDxHealth raised $20 million through a registered direct placement to strengthen its balance sheet and support commercial expansion. Looking ahead, management expressed confidence in returning to positive adjusted EBITDA as the year progresses but noted potential volatility due to seasonality and unanticipated reimbursement issues affecting prior performance.
